Hepatitis C Virus Infection Among Injection Drug Users: Survival Analysis of Time to Seroconversion
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Time to hepatitis C virus (HCV) seroconversion in initially seronegative injection drug users has not been directly measured, and public health planning would benefit from specifying the window of opportunity for prevention of infection, and factors that affect timing of infection. METHODS: Four hundred eighty-four HCV antibody-negative injection drug users in Seattle, Washington were followed a median of 2.1 years to observe seroconversion. We examined time to HCV seroconversion in relation to subject characteristics using the Kaplan-Meier method and Cox proportional hazards regression. A weighted-average time to HCV seroconversion was calculated among new injectors (injecting < or = 2 years) using seroprevalence and seroincidence data. RESULTS: There were 134 HCV seroconversions (11.6 per 100 person-years at risk; the 25th percentile of time to seroconversion was 26.2 months). Injection with a syringe used by another injector (adjusted hazards ratio = 1.8; 95% confidence interval = 1.3-3.0) and sharing a cooker or cotton (1.8; 1.0-3.1) were associated with time to HCV seroconversion. Using the estimate of the mean time to seroconversion from first injection in new injectors who were HCV antibody-negative at enrollment (5.4 years), and the midpoint between first injection and study enrollment in new injectors who were HCV antibody-positive at enrollment (0.6 years), the weighted-average time to seroconversion after beginning to inject was estimated to be 3.4 years. CONCLUSION: The period of susceptibility to HCV infection in the majority of drug injectors appears to be long enough to justify the allocation of substantial resources toward interventions to reduce injection-related risk behavior in these individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2001) · American Journal of Public Health · doi:10.2105/ajph.91.6.927 · Cited by 1,060
Cited by
The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002
Armstrong, G. L., Wasley, A., Simard, E. P., McQuillan, G. M., Kuhnert, W. L., & Alter, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00004 · Cited by 1,955
Hagan, H., Pouget, E. R., & Des Jarlais, D. C. (2011) · Journal of Infectious Diseases · doi:10.1093/infdis/jir196 · Cited by 313
Self-citationGlobal control of hepatitis C: where challenge meets opportunity
Thomas, D. L. (2013) · Nature Medicine · doi:10.1038/nm.3184 · Cited by 280
Des Jarlais, D. C., Perlis, T., Arasteh, K., Torian, L. V., Hagan, H., Beatrice, S., Smith, L., Wethers, J., Milliken, J., Mildvan, D., et al. (2005) · AIDS · doi:10.1097/01.aids.0000192066.86410.8c · Cited by 163
Self-citationGrebely, J., Lima, V. D., Marshall, B. D. L., Milloy, M.-J., DeBeck, K., Montaner, J., Simo, A., Krajden, M., Dore, G. J., Kerr, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097726 · Cited by 48
Metadata
- Authors
- Hagan, H., Thiede, H., & Des Jarlais, D. C.
- Venue
- Epidemiology
- Published
- 2004-09
- Volume
- 15
- Issue
- 5
- Pages
- 543-549
- ISSN
- 1044-3983 (ISSN-L)
- OpenAlex
- W1967536881
- Cited by
- 170
- References
- 1
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatitis C Virus Infection Among Injection Drug Users: Survival Analysis of Time to Seroconversion. https://app.cochat.ai/papers/10.1097/01.ede.0000135170.54913.9d
- The paper
- Hagan, H., Thiede, H., & Des Jarlais, D. C. (2004). Hepatitis C Virus Infection Among Injection Drug Users: Survival Analysis of Time to Seroconversion. Epidemiology. https://doi.org/10.1097/01.ede.0000135170.54913.9d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.